CollPlant Launches BioFlex — Ready-to-Print Human Collagen Bioprinting Kit for DLP

CollPlant (NASDAQ: CLGN), an Israeli regenerative medicine company, has launched BioFlex — a ready-to-print rhCollagen-based kit designed specifically for Digital Light Processing (DLP) 3D bioprinting applications.

What is BioFlex?

BioFlex is a formulation-ready system that includes CollPlant's proprietary recombinant human collagen (rhCollagen) combined with Collink.3D 50, a biodegradable polymer component. The kit also includes photoactive agents optimized for high-resolution DLP printing.

Unlike traditional collagen sources, rhCollagen is animal-free, eliminating concerns about immunogenicity and disease transmission from animal-derived materials.

Key Features

• Tunable mechanical properties — Researchers can adjust polymer concentrations to customize elasticity, strength, and structural performance
• Rapid formulation workflow — Eliminates the need for extensive component screening
• High-resolution printing — Optimized for DLP bioprinters
• Reproducible results — Guided formulation process ensures consistency across experiments

Applications

BioFlex is designed for:

• Drug discovery — Advanced tissue models for pharmaceutical testing
• Tissue engineering — Engineered tissues for regenerative medicine
• Transplantable organs — Research toward organ fabrication
• Vascular channels — Bioprinted perfusable structures

Why This Matters

The bioprinting field has long struggled with reproducibility and scalability. Traditional bioink development requires extensive trial-and-error to achieve the right mechanical properties. BioFlex's guided workflow significantly reduces development time while maintaining flexibility.

CollPlant's recombinant human collagen platform has been used in medical implants and aesthetics. Now, by packaging it as a ready-to-print kit, they're making this technology more accessible to researchers and companies working on the frontier of regenerative medicine.

The global bioprinting market is projected to grow significantly as advancements in materials science enable more functional tissues to be printed. CollPlant's BioFlex could accelerate this timeline by lowering the barrier to entry for high-quality bioprinting research.